Filgrastim Recruiting Phase 2 Trials for Myelodysplastic Syndrome / Acute Myeloid Leukemia (AML) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03356080DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess